VNDA — Vanda Pharmaceuticals Inc.

Is VNDA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Vanda Pharmaceuticals Inc. (VNDA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $5.44. The rating moved from Neutral to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

Vanda Pharmaceuticals Inc. (VNDA) is a small-cap biopharma with a concentrated revenue base and typical early-stage/specialty commercial risks. Near-term performance will be driven by product sales trends, cash runway and any clinical or licensing catalysts; broader market risk-on tone could provide short-term support but fundamentals (payor dynamics, potential dilution, and regulatory outcomes) dominate medium-term prospects. Investors should watch upcoming corporate announcements, cash/burn metrics, and any clinical readouts for directional clarity.

Key factors

  • Concentrated product portfolio with revenue largely dependent on a small number of marketed drugs, which drives sensitivity to sales trends and payer decisions
  • Modest current market capitalization and liquidity typical of small-cap biopharma, leading to higher volatility but also opportunity for outsized moves on clinical or commercial news
  • Recent macro tone (mild risk-on) can support speculative biotech interest in the near term but does not change underlying fundamentals
  • Potential near-term catalysts include clinical readouts, label expansions, or licensing deals that could materially re-rate the equity if positive
  • Cost structure and cash runway are key determinants; limited diversification increases the importance of capital raising risk and potential dilution
  • Competitive and reimbursement pressures in the therapeutic areas served could constrain pricing and uptake

Risks

  • Clinical trial failure or negative readouts for pipeline programs that would remove upside catalysts
  • Insufficient cash runway requiring equity raises that dilute existing shareholders
  • Adverse regulatory decisions, label restrictions, or slower-than-expected approvals/expansions
  • Payer resistance, pricing pressure, or formulary exclusions that reduce sales visibility
  • High single-product concentration risk amplifying revenue shocks from any commercial disruption
  • Low liquidity and investor attention leading to larger-than-normal intraday moves and bid-ask impacts
  • Macro/market repricing (rates, sector rotations) could sharply reduce appetite for small-cap biotech risk

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for VNDA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.